Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Melanoma Clinical Trials in Tennessee | 340 Studies

Clinical Trials MelanomaTennessee

Melanoma Clinical Trials in Tennessee

Find 340 clinical trials for melanoma near Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 121-140 of 340 trials

CompletedA Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine…NCT01721746·Phoenix, Arizona and 94 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedTreatment for Subjects With Unresectable Stage III or Stage IV MelanomaThis is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the…NCT00110994·Tucson, Arizona and 13 others

CompletedMDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaThe purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients…NCT00094653·Tucson, Arizona and 208 others

CompletedAn Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's LymphomaThis first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of…NCT02783300·Denver, Colorado and 14 others

CompletedAn Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadThe purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and…NCT02658890·Tucson, Arizona and 46 others

RecruitingComparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage MelanomaThis phase III trial compares the effect of wide local excision (WLE) alone to usual care with WLE plus sentinel lymph node (SLN) biopsy for the treatment of older adults with…NCT07068074·Birmingham, Alabama and 180 others

TerminatedStudy CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung…NCT02771626·Scottsdale, Arizona and 16 others

Active not recruitingStudy of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients…NCT03767348·Birmingham, Alabama and 50 others

CompletedTrial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsThis research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409…NCT01390818·Scottsdale, Arizona and 7 others

TerminatedA Study of Ladiratuzumab Vedotin in Advanced Solid TumorsThis trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors.NCT04032704·Chandler, Arizona and 65 others

CompletedA Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionThe purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or…NCT05297565·Fort Wayne, Indiana and 15 others

Active not recruitingA Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsThis is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in…NCT05581004·San Francisco, California and 35 others

CompletedOpen-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or LymphomaMEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts.NCT00687622·Scottsdale, Arizona and 11 others

CompletedA Treatment Combination for Patients With Unresectable Stage III or Stage IV MelanomaThe objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and…NCT00111007·Birmingham, Alabama and 65 others

Active not recruitingA Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsThis is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or…NCT02988960·Los Angeles, California and 21 others

CompletedEfficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaThe purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.NCT02388906·Little Rock, Arkansas and 135 others

TerminatedStudy of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone…NCT06984328·Nashville, Tennessee and 1 other

Active not recruitingAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab…NCT03897881·Tucson, Arizona and 22 others

RecruitingStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)…NCT04198766·Duarte, California and 41 others

UnknownDose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult…NCT03634982·Scottsdale, Arizona and 11 others

PreviousPage 7 of 17Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma